Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity.
We have evaluated the use of an ultrasensitive reverse transcriptase (RT) activity assay to monitor plasma viremia in two human immunodeficiency virus type 1 (HIV-1) group O-infected patients treated with stavudine, lamivudine, and indinavir. After a initial decline in RT levels observed at 4 weeks of therapy, RT-based plasma viremia returned to baseline values at 28 or 44 weeks of treatment. The rebound in levels of RT activity was associated with the detection of phenotypic resistance to lamivudine and with the Met184Val mutation. Analysis of RT activity in plasma provides a sequence-independent means of monitoring virus loads in HIV-1 group O-infected patients.
García Lerma
J G
JG
HIV and Retrovirology Branch, Division of AIDS, TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Soriano
V
V
Mas
A
A
Quiñones-Mateu
M E
ME
Arts
E J
EJ
Heneine
W
W
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D005260:Female; D016701:Guinea; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology; D054303:HIV Reverse Transcriptase / Q000097:blood*; D015497:HIV-1 / Q000145:classification* / Q000201:enzymology; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D013030:Spain; D018119:Stavudine / Q000627:therapeutic use; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy
D019380:Anti-HIV Agents; D019259:Lamivudine; D019469:Indinavir; D018119:Stavudine; D054303:HIV Reverse Transcriptase